1. Introduction {#sec1}
===============

Recent studies have reported on long noncoding RNA (lncRNA) expression profiling in various human tissues \[[@B1]\]; however, expression profile of lncRNA in human epicardial adipose tissue (EAT) has yet to be described in detail. It is known that a large proportion of the mammalian genome is transcribed as lncRNA, which resides within or between coding genes. In addition, many lncRNAs have been shown to be functional and involved in specific physiological and pathological processes, through transcriptional or posttranscriptional regulatory mechanisms \[[@B2], [@B3]\]. To date, however, lncRNAs have never been included in analyses of the human EAT transcriptome. EAT is a key cardiometabolic factor, where, by releasing various inflammatory factors \[[@B4]\], EAT can modulate cardiac function and correlate with heart failure (HF) \[[@B5], [@B6]\], independently of metabolic status or the presence of coronary artery disease (CAD).

In the present study, we sought to supplement EAT lncRNA and mRNA expression profiles to provide a more complete picture of the myocardial transcriptional landscape in heart failure and also provide possible biomarkers for HF.

2. Materials and Methods {#sec2}
========================

2.1. Study Participants {#sec2.1}
-----------------------

EAT samples were taken from 10 CAD patients who underwent coronary artery bypass graft surgery, in the Department of Heart Center, Beijing Chao-yang Hospital of Capital Medical University. Subjects were divided into two groups: HF group (n=5) and non-HF group (n=5). HF group included patients with Brain Natriuretic Peptide (BNP)\>500ng/L and abnormal echocardiography finding (left ventricular end diastolic diameter \[LVEDD\]\>50mm in female and \>55mm in male and left ventricular ejection fraction \[LVEF\]\<50%); non-HF group included patients with BNP\<100 ng/L and normal views in echocardiography. The protocol was approved by the Ethics Committee of Beijing Chao-yang Hospital affiliated with Capital Medical University and written informed consent was obtained from participants before the study.

2.2. RNA Sequencing Procedure {#sec2.2}
-----------------------------

Total RNA was extracted from the EAT and quantified using a NanoDrop ND-1000 instrument. 1-2*μ*g total RNA was used to prepare the sequencing library in the following steps: (1) Total RNA is enriched by oligo (dT) magnetic beads (rRNA removed). (2) Using KAPA Stranded RNA-Seq Library Prep Kit (Illumina), RNA-seq library preparation incorporates dUTP into the second cDNA strand and makes the RNA-seq library strand-specific. (3) After completing, libraries were qualified with Agilent 2100 Bioanalyzer and quantified by absolute quantification qPCR method. (4) Sequence the libraries on the Illumina HiSeq 4000 instrument (we followed the methods of Wang et al. 2019 \[[@B7]\]).

2.3. Quantitative RT-PCR {#sec2.3}
------------------------

qRT-PCR was used to measure selected lncRNA ENST00000610659 and UNC93B1 mRNA. Total RNA samples were extracted from the EAT samples using TRIzol (Invitrogen, Carlsbad, CA). The relative expression levels of mRNA and lncRNA were quantified using ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, USA) according to standard methods. lncRNA ENST00000610659: the forward primer was 5′ CGGCTTCAACAAGACGGTTC 3′, the reverse primer was 5′ AAGGCTCCACTCCGCACAAA 3′; UNC93B1 mRNA: the forward primer was 5′ GCTCACCTACGGCGTCTACC 3′, the reverse primer was 5′ CGGTAGGTCTCGT CGTAGTGC 3′.

2.4. Statistical Analysis {#sec2.4}
-------------------------

R package was used to calculate the FPKM value and differential expression for gene and transcript level and perform hierarchical clustering, GO enrichment, pathway analysis, scatter plots, and volcano plots with the differentially expressed genes. Descriptive statistics for each variable were determined. Continuous variables were expressed as the mean ± SD and compared using unpaired Student\'s t-test, and categorical variables were expressed as percentages and numbers and were compared using the chi-squared test. Significant GO enrichment and pathways were selected by Fisher\'s exact test, and p\<0.05.

3. Results {#sec3}
==========

3.1. Characteristics of Participants {#sec3.1}
------------------------------------

The present study comprised 10 CAD patients (5 with HF and 5 without). The main clinical characteristics of the two groups are summarized in [Table 1](#tab1){ref-type="table"}. There were no significant differences in subject characteristics between the two groups; they were well balanced with regard to main clinical and laboratory characteristics. The CAD patients with HF had higher BNP level and LVEDD and lower LVEF.

3.2. RNA Sequencing Data {#sec3.2}
------------------------

Using RNA sequencing, we detected 46760 transcripts (including 35673 protein-coding and 11087 non-protein-coding with linear structure and length\>200bp) corresponding to 15554 genes in EAT in total. The top 30 highly expressed protein-coding and non-protein-coding transcripts are summarized in [Table 2](#tab2){ref-type="table"}.

Scatter plot ([Figure 1](#fig1){ref-type="fig"}) was performed to group lncRNA and mRNA and display the levels of lncRNA and mRNA in CAD patients with and without HF according to their expression levels among samples, and the results indicated that the lncRNA and mRNA expression profiles in CAD patients with HF were distinctly different from those in CAD patients without HF. 85 lncRNA and 866 mRNA whose levels changed significantly (p\<0.05) were identified, including 45 upregulated and 40 downregulated lncRNA, as well as 404 upregulated and 462 downregulated mRNA.

Using a 2-fold expression difference as a cutoff, a total of 30 differentially expressed lncRNAs (17 upregulated and 13 downregulated) ([Figure 2](#fig2){ref-type="fig"}, [Table 3](#tab3){ref-type="table"}) and 278 differentially expressed mRNAs (129 upregulated and 149 downregulated) were discriminated between CAD patients with and without HF ([Figure 2](#fig2){ref-type="fig"}). Among them, lncRNA ENST00000610659 was the top upregulated lncRNA with highest fold change and corresponded to UNC93B1 gene, which was proved to be related to HF and encoded UNC93B1 protein regulating toll-like receptor signaling. lncRNA ENST00000610659 and UNC93B1 mRNA were both significantly increased in HF patients in qRT-PCR validation (p=0.040 for lncRNA ENST00000610659 and p=0.019 for UNC93B1 mRNA) ([Figure 3](#fig3){ref-type="fig"}). lncRNA ENST00000610659 might be a potential biomarker for HF.

3.3. GO and KEGG Pathway Analysis of Differentially Expressed mRNAs {#sec3.3}
-------------------------------------------------------------------

The Gene Ontology (GO) project ([Figure 4](#fig4){ref-type="fig"}) provided a controlled vocabulary to describe gene and gene product attributes in any organism. The ontology covered three domains: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF). For upregulated genes, the top enriched GO terms in three domains were regulation of lymphocyte activation (GO:0051249) in BP, T cell receptor complex (GO:0042101) in CC, and phosphotyrosine residue binding (GO:0001784) in MF; for downregulated genes, those were oxidation reduction process (GO:0055114) in BP, extracellular space (GO:0005615) in CC, and oxidoreductase activity (GO:0016491) in MF, respectively.

Pathway analysis ([Figure 5](#fig5){ref-type="fig"}) showed that, when comparing to controls, 17 pathways were significantly upregulated while 4 pathways were significantly downregulated. The top 3 significantly upregulated pathways were T cell receptor signaling pathway (hsa04660), primary immunodeficiency (hsa05340), and endometrial cancer (hsa05213). Meanwhile, the significantly downregulated pathways were drug metabolism cytochrome P450 (hsa00982), tyrosine metabolism (hsa00350), complement and coagulation cascades (hsa04610), and Jak-STAT signaling pathway (hsa04630).

4. Discussion {#sec4}
=============

In the present study, we assessed the expression profiles of EAT lncRNA and mRNA in CAD patients with and without HF. The results showed a total of 35673 mRNA and 11087 lncRNA corresponding to 15554 genes in EAT were detected, and using a 2-fold expression difference as a cutoff, a total of 30 differentially expressed lncRNAs (17 upregulated and 13 downregulated) and 278 differentially expressed mRNAs (129 upregulated and 149 downregulated) were discriminated between CAD patients with and without HF.

The differentially expressed lncRNAs corresponded to genes associated with inflammatory response or other factors which are involved in HF. UNC93B1, the top upregulated gene lncRNA corresponded to, encodes UNC93B1 protein that is involved in innate and adaptive immune response by regulating toll-like receptor signaling \[[@B8], [@B9]\] and is proved to be related to left ventricular diastolic function, heart failure morbidity, and mortality \[[@B10]\]. RBL2 is related to TGF-beta signaling \[[@B11]\]. LINC00963 encodes lncRNA963 playing an important role in chronic renal failure, which is closely associated with chronic diseases such as congestive heart failure \[[@B12]\]. TRIM52 encodes TRIM52 protein that positively regulates the nuclear factor-kappa B signaling pathway \[[@B13]\]. RPS21 (also known as HLDF) encodes HLDF protein that is involved in the mechanisms of blood pressure regulation \[[@B14]\]. AMOTL2 is required for migration and proliferation of endothelial cells during angiogenesis \[[@B15]\]. FBLN5 protein expression significantly decreases in human aneurysmatic aortas and may mediate cell-extracellular matrix interactions and elastic fibre assembly by inflammation \[[@B16]\]. TMTC1 is associated with the risk of incident HF \[[@B17]\]. LRRFIP1 is associated with adiposity and inflammation \[[@B18]\], and LRRFIP1 protein may regulate platelet function \[[@B19]\].

EAT refers to the fat depot that exists on the surface of the myocardium and is contained entirely beneath the pericardium, which generates various inflammatory factors \[[@B20], [@B21]\]. Factors released from EAT have vasocrine and paracrine effects on the myocardium contributing to modulating properties on cardiac function \[[@B4], [@B22]\]. As our study showed, lncRNA can also be released from EAT and may be involved in HF; top upregulated lncRNA in HF corresponded to genes associated with inflammatory response and top upregulated enriched GO terms and KEGG pathway of mRNA were also about inflammatory cells activity.

The present study showed the expression profiles of EAT lncRNA and mRNA in CAD patients and also characterized specific EAT lncRNA expression in HF. The EAT lncRNA may be important effector molecules for cardiovascular disease. Through the paracrine and vasocrine transmission, the EAT lncRNA may diffuse across the interstitial fluid or blood into the myocardium to be involved in the development of HF. Our data supplement lncRNA expression profiles in the EAT for lncRNA identifying in heart tissues and also provide possible biomarkers for HF, and further studies are needed to prove it.
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![The scatter plot of the differential expressed (p\<0.05) lncRNA (a) and mRNA (b) in patients with heart failure (HF) and without heart failure (non-HF) (red or green represented upregulated or downregulated genes, respectively); 85 lncRNA and 866 mRNA were identified, including 45 upregulated and 40 downregulated lncRNA, as well as 404 upregulated and 462 downregulated mRNA.](BMRI2019-3945475.001){#fig1}
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###### 

Participants Characteristics.

                              CAD with HF     CAD without HF   P value
  --------------------------- --------------- ---------------- ---------
  Male, n(%)                  2(40)           3(60)            0.999
  Age, years                  67.8±5.0        60.8±8.1         0.139
  BMI, kg/m^2^                23.8±4.6        25.0±5.5         0.718
  Diabetes, n(%)              2(40)           2(40)            1.000
  Hypertension, n(%)          4(80)           5(100)           1.000
  HbA1c, %                    6.85±0.87       7.00±1.81        0.871
  Total cholesterol, mmol/L   3.67±3.07       3.60±1.52        0.965
  LDL-C, mmol/L               2.34±2.52       2.24±1.46        0.941
  HDL-C, mmol/L               0.84±0.53       0.70±0.12        0.580
  Triglyceride, mmol/L        0.89±0.38       1.86±0.89        0.055
  Creatinine, *μ*mol/L        88.2±25.2       76.8±16.8        0.424
  Uric acid, *μ*mol/L         363.2±82.4      357.0±69.3       0.901
  BNP, pg/ml                  1795.4±1053.3   76.4±22.6        0.006
  LVEDD, mm                   60.0±5.9        47.5±5.2         0.007
  LVEF, %                     44.2±10.2       62.0±4.8         0.008

Notes: BMI, body mass index; HbA1c, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BNP, brain natriuretic peptide; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction.

###### 

The 30 highly expressed protein-coding and non protein-coding transcripts in EAT in CAD patients.

  Track ID             Gene Name   Transcript Type        Length(bp)   Protein
  -------------------- ----------- ---------------------- ------------ ---------
  ENST00000165086.8    NPIPB4      Processed transcript   464          No
  ENST00000173785.4    KLF6        Processed transcript   925          No
  ENST00000214893.9    ERMP1       Processed transcript   4974         No
  ENST00000216463.8    TIMM9       Processed transcript   1075         No
  ENST00000216520.6    ERH         Processed transcript   668          No
  ENST00000217890.10   ARSD        Processed transcript   2160         No
  ENST00000230914.4    MRPS30      Processed transcript   4331         No
  ENST00000233699.8    POLE4       Processed transcript   602          No
  ENST00000237177.10   CASP8AP2    Processed transcript   6719         No
  ENST00000244070.7    PPP4R1L     Processed transcript   1474         No
  ENST00000253320.8    TXLNGY      Retained intron        7299         No
  ENST00000254109.9    CLUHP3      Processed transcript   1812         No
  ENST00000254299.8    GCH1        Processed transcript   2901         No
  ENST00000256692.5    PLEKHA8P1   Processed transcript   1839         No
  ENST00000263511.8    CROCCP3     Processed transcript   5368         No
  ENST00000264785.11   WDR1        Processed transcript   549          No
  ENST00000265450.5    TSPAN14     Processed transcript   2588         No
  ENST00000265870.7    SLC25A16    Processed transcript   2295         No
  ENST00000267869.8    GTF2A2      Processed transcript   518          No
  ENST00000267918.9    ANP32A      Processed transcript   1084         No
  ENST00000273411.2    RPL39P5     Processed transcript   449          No
  ENST00000274820.7    RPL13P5     Processed transcript   349          No
  ENST00000276096.10   EBP         Processed transcript   904          No
  ENST00000282943.9    ADGRA3      Processed transcript   3534         No
  ENST00000286777.6    RWDD2B      Processed transcript   1625         No
  ENST00000294661.8    C1orf52     Processed transcript   3391         No
  ENST00000295549.8    LINC01116   lincRNA                1407         No
  ENST00000295748.7    AZI2        Processed transcript   3127         No
  ENST00000296031.4    CXCL2       Processed transcript   577          No
  ENST00000296325.9    LRPAP1      Processed transcript   1078         No
  ENST00000361624.2    MT-CO1      Protein coding         1542         513aa
  ENST00000362079.2    MT-CO3      Protein coding         784          261aa
  ENST00000361390.2    MT-ND1      Protein coding         956          318aa
  ENST00000361381.2    MT-ND4      Protein coding         1378         459aa
  ENST00000361453.3    MT-ND2      Protein coding         1042         347aa
  ENST00000361789.2    MT-CYB      Protein coding         1141         380aa
  ENST00000361739.1    MT-CO2      Protein coding         684          227aa
  ENST00000361851.1    MT-ATP8     Protein coding         207          68aa
  ENST00000331825.11   FTL         Protein coding         871          175aa
  ENST00000361335.1    MT-ND4L     Protein coding         297          98aa
  ENST00000361567.2    MT-ND5      Protein coding         1812         603aa
  ENST00000361227.2    MT-ND3      Protein coding         346          115aa
  ENST00000361899.2    MT-ATP6     Protein coding         681          226aa
  ENST00000320868.9    HBA1        Protein coding         577          142aa
  ENST00000331523.6    EEF1A1      Protein coding         1923         462aa
  ENST00000327726.10   CFD         Protein coding         1201         253aa
  ENST00000302754.5    JUNB        Protein coding         1830         347aa
  ENST00000239938.4    EGR1        Protein coding         3137         543aa
  ENST00000356524.9    SAA1        Protein coding         518          122aa
  ENST00000633942.1    PLIN4       Protein coding         6484         1372aa
  ENST00000367029.5    G0S2        Protein coding         876          103aa
  ENST00000309311.7    EEF2        Protein coding         3158         858aa
  ENST00000251595.11   HBA2        Protein coding         576          142aa
  ENST00000335295.4    HBB         Protein coding         628          147aa
  ENST00000256104.4    FABP4       Protein coding         941          132aa
  ENST00000451311.7    TMSB4X      Protein coding         622          44aa
  ENST00000233143.6    TMSB10      Protein coding         461          44aa
  ENST00000330871.3    SOCS3       Protein coding         2734         225aa
  ENST00000336615.9    PNPLA2      Protein coding         2416         504aa
  ENST00000300055.10   PLIN1       Protein coding         2916         522aa

Note: EAT, epicardial adipose tissue; CAD, coronary artery disease; Track ID, The transcript name in Ensembl database; Gene Name, The corresponding gene name of transcript; Transcript Type, the biotype of transcript; Protein, the residue number of protein.

###### 

Differentially expressed lncRNA in EAT in CAD patients with HF compared with CAD patients without HF.

  lncRNA            Type                     Regulation   Gene Name      Fold Change   P Value
  ----------------- ------------------------ ------------ -------------- ------------- ---------
  ENST00000610659   exon sense-overlapping   Up           UNC93B1        4.778         0.0118
  ENST00000379935   natural antisense        Up           RBL2           3.711         0.0347
  ENST00000603195   exon sense-overlapping   Up           ZSWIM8         3.329         0.0039
  ENST00000439904   exon sense-overlapping   Up           SLC25A16       2.955         0.0179
  ENST00000622120   intergenic               Up           LINC00963      2.952         0.0000
  ENST00000514805   exon sense-overlapping   Up           TRIM52         2.901         0.0294
  ENST00000492356   exon sense-overlapping   Up           RPS21          2.869         0.0461
  ENST00000394225   exon sense-overlapping   Up           NDUFC1         2.840         0.0331
  ENST00000548989   exon sense-overlapping   Up           CRIP2          2.247         0.0248
  ENST00000465589   exon sense-overlapping   Up           OBSL1          2.229         0.0067
  ENST00000398078   exon sense-overlapping   Up           PDXK           2.111         0.0157
  ENST00000476113   exon sense-overlapping   Up           TCEA2          2.111         0.0223
  ENST00000421064   natural antisense        Up           AP000347.2     2.099         0.0220
  ENST00000470322   exon sense-overlapping   Up           ACTR1A         2.083         0.0304
  ENST00000587762   intergenic               Up           AC020916.1     2.054         0.0443
  ENST00000512955   exon sense-overlapping   Up           AMOTL2         2.052         0.0164
  ENST00000508948   exon sense-overlapping   Up           ARRDC3         2.012         0.0289
  ENST00000543826   exon sense-overlapping   Down         ADGRD1         0.161         0.0021
  ENST00000467318   exon sense-overlapping   Down         DDX56          0.243         0.0126
  ENST00000556961   exon sense-overlapping   Down         FBLN5          0.251         0.0033
  ENST00000505923   exon sense-overlapping   Down         WDFY3          0.283         0.0221
  ENST00000578571   exon sense-overlapping   Down         PTPRM          0.305         0.0360
  ENST00000427261   intergenic               Down         RP11-640M9.2   0.331         0.0051
  ENST00000319685   exon sense-overlapping   Down         TMTC1          0.370         0.0256
  ENST00000493951   exon sense-overlapping   Down         TACC2          0.391         0.0341
  ENST00000480603   exon sense-overlapping   Down         PPIA           0.414         0.0048
  ENST00000345896   exon sense-overlapping   Down         CERS2          0.453         0.0391
  ENST00000498053   exon sense-overlapping   Down         LRRFIP1        0.475         0.0350
  ENST00000467178   exon sense-overlapping   Down         CIZ1           0.486         0.0448
  ENST00000468975   exon sense-overlapping   Down         ARFGAP1        0.495         0.0128

Note: EAT, epicardial adipose tissue; CAD, coronary artery disease; HF, heart failure; lncRNA, The lncRNA name in Ensembl database; Type, the type of lncRNA; Regulation, the regulation expression of lncRNA; Gene Name, The corresponding gene name of lncRNA.
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